I am a
Home I AM A Search Login

Papers of the Week

2022 Sep 04

Infect Dis Ther

First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults.


Prativadibhayankaram VS, Lee L S-U, Lye D, Xiaoying X, Nellore R, Pendharkar V, Hentze H, Guan S, Ayers BJ, Seah SGK, Chye D H, Talib NSN, Kaliaperumal N, Ong W Y, Wong Z X, Au VB, Alok A, Connolly JE, Boyd-Kirkup JD, Ingram PJ, et al.
Infect Dis Ther. 2022 Sep 04.
PMID: 36058990.


AOD01 is a novel, fully human immunoglobulin (Ig) G1 neutralizing monoclonal antibody that was developed as a therapeutic against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). This first-in-human study assessed safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AOD01 in healthy volunteers.